Mixed Phase III results for Sucampo's lubiprostone in opioid-related bowel dysfunction
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals has reported mixed top-line results from two Phase III trials with its gastrointestinal product lubiprostone for the management of opioid-induced bowel (OBD) dysfunction in patients with chronic, non-cancer pain.